Search - tctmd.com

Displaying 401 - 420 of 571

Sort: Relevancy | Date

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Presenter: Stephen G. Ellis, John A. Ormiston, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Presenter: Stephen G. Ellis, John A. Ormiston, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny!

Presenter: Stephen G. Ellis, John A. Ormiston, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Presenter: Stephen G. Ellis, John A. Ormiston, Robert A. Byrne

October 11, 2015

Presentation TCT 2015

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston, Sripal Bangalore

October 11, 2015

Presentation TCT 2015

Design of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Presenter: Stephen G. Ellis, John A. Ormiston

October 11, 2015

Presentation TCT 2015

Debate: For SFA Disease I Prefer a Drug-Eluting Stent!

Presenter: Julie Logan, William A. Gray

October 11, 2015

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

Presentation CICT 2015

Drug Eluting Femoral Stents Where does it fit in my practice?

Presenter: Yazan Khatib

July 31, 2015

Presentation CCVVC 2015

Endovascular Management of SFA Instent Restenosis: Role of Atherectomy Drug-Eluting Stents

Presenter: Craig M. Walker

June 18, 2015

Presentation CCVVC 2015

Drug Eluting Stents in the treatment of SFA disease: Data and Current Trends

Presenter: Suhail Dohad

June 18, 2015

Presentation Fellows 2015

Drug-Eluting Stents: Past, Present, and Future

Presenter: Manish A. Parikh, Roxana Mehran, Gregg W. Stone

May 15, 2015

Presentation CADECI 2015

The future of Drug-Eluting Stent

Presenter: Renu Virmani

February 18, 2015

Presentation AHA 2014

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Presenter: C.Kaiser

November 16, 2014

Presentation TCT 2014

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Freek Nijhoff

September 16, 2014

Presentation TCT 2014

TCT 94: Long-term Clinical Outcomes of Patients with Coronary Artery Aneurysm After Drug-Eluting Stent Implantation

Presenter: Thomas F. Luscher, Hyung Joon Joo, MD

September 16, 2014

Presentation TCT 2014

Impact of Pioglitazone on Cardiovascular Events in Patients with Diabetes Mellitus after Drug-eluting Stent Implantation: Evidence from 3-Year Follow-up Results of the J-DESsERT___

Presenter: Hiroyoshi Yokoi

September 16, 2014

Presentation TCT 2014

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

Presenter: Kazushige Kadota

September 16, 2014

Presentation TCT 2014

BIOTRONIK-Safety and Clinical Performance of the Drug Eluting Orsiro Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions-II (BIOFLOW-II) ? 2 Year___

Presenter: Rafael Ruiz-Salmeron

September 16, 2014

Presentation TCT 2014

Drug Eluting Stents Versus Coronary Artery Bypass Graft surgery for Isolated Proximal Left Anterior Descending Artery Stenosis: A Meta-analysis

Presenter: Alok Saurav

September 16, 2014

Advertisement

Durable-Polymer DES 5-Year Outcomes: RESOLUTE Update

Durable-Polymer DES 5-Year Outcomes: XIENCE/PROMUS and PROMUS Element Update

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny!

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Clinical Outcomes of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Design of Current-Generation Durable-Polymer Drug-Eluting Stents: More Alike or Different?

Debate: For SFA Disease I Prefer a Drug-Eluting Stent!

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Drug Eluting Femoral Stents Where does it fit in my practice?

Endovascular Management of SFA Instent Restenosis: Role of Atherectomy Drug-Eluting Stents

Drug Eluting Stents in the treatment of SFA disease: Data and Current Trends

Drug-Eluting Stents: Past, Present, and Future

The future of Drug-Eluting Stent

Long-term Outcome of Biodegradable Compared to Durable Polymer Drug-Eluting Stents and Bare Metal Stents – Main Results of a Prospective Randomized Trial

Antirestenotic Efficacy in the Treatment of In-Stent Restenosis: A Comparison of Two Paclitaxel Drug-Eluting Balloons With Different Coatings

TCT 94: Long-term Clinical Outcomes of Patients with Coronary Artery Aneurysm After Drug-Eluting Stent Implantation

Impact of Pioglitazone on Cardiovascular Events in Patients with Diabetes Mellitus after Drug-eluting Stent Implantation: Evidence from 3-Year Follow-up Results of the J-DESsERT___

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

BIOTRONIK-Safety and Clinical Performance of the Drug Eluting Orsiro Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions-II (BIOFLOW-II) ? 2 Year___

Drug Eluting Stents Versus Coronary Artery Bypass Graft surgery for Isolated Proximal Left Anterior Descending Artery Stenosis: A Meta-analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content